Sold as Cenestin, Synthetic Conjugated Estrogens A. Every FDA application for this active ingredient. Boxed warning
As of Nov 22, 2026, FDA lists 2 applications for Estrogens, conjugated synthetic a (sold as Cenestin, Synthetic Conjugated Estrogens A), first approved Mar 24, 1999, with 2 new uses approved and 0 published complete response letters.
| Mar 24, 1999 | CenestinNDA 20992 · New dosage form | Aspen | 29 | Discontinued |
| Nov 28, 2008 | Synthetic Conjugated Estrogens ANDA 21788 · New dosage form | Teva Women's Health | 0 | Discontinued |
| Study | Phase | Status | Posted |
|---|---|---|---|
| Neoadjuvant Dalpiciclib + AI → SHR-A1811 for HR+/HER2-Low Breast CancerBreast Cancer, HR Positive/HER2 Low Breast Cancer · Tang-Du Hospital | Phase 2 | Not yet recruiting | Jun 1, 2026 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA